DOCSLIB.ORG

Annual Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign. • Project Zero. Huffington Post offers a 360-degree view of three neglected tropical diseases, elephantiasis, river blindness and sleeping sickness, through its Project Zero virtual reality experience. • Minutes to Die. We are screening the new documentary Minutes to Die that looks at venomous snakebite through the issues of snakebite victims, researchers at antivenom labs and public officials at the World Health Organization. TropMed17 also provides attendees with free Wi-Fi, a meeting App and recordings of each session available within 48 hours after the session has taken place. Lastly, we are grateful to our sponsors and exhibitors, who contribute importantly to our meeting and the field. Check out their offerings and information at the Opening Reception, along with complimentary food and drink. Whatever you’re looking for in the world of tropical medicine and global health, you’ll find it here. Glad you’ve joined us. Daniel G. Bausch, MD, Patricia F. Walker, Karen A. Goraleski MPH&TM, FASTMH MD, DTM&H, FASTMH Executive Director Scientific Program Chair President 3 4 5 ASTMH Thanks the Following Sponsors LEADER Takeda Pharmaceuticals International AG PARTNER PARTNER Celgene Corporation CONTRIBUTOR TECHLAB Inc. CONTRIBUTOR Bayer CONTRIBUTOR Sanofi Pasteur FRIEND FRIEND ASTMH Thanks the Following Supporters Sanofi Pasteur Gilead ASTMH Thanks the Following Donors William A. Petri, Sr. and Dr. Ann E. Petri Petri Family Anonymous 6 Schedule- Table of Contents at-a-Glance Annual Meeting Sponsors, Supporters and Donors ....6 About ASTMH ................................7 ASTMH Membership ...........................8 Schedule-at-a-Glance ...........................10 Sponsors Exhibitors/ Program Changes..............................11 Meeting Room Directory ........................20 ASTMH Council ...............................21 ASTMH Subgroups and Committees ...............23 Scientific Program Committee ....................26 Saturday November 4 Fellowships, Travel Awards and Grants .............28 Subgroup Awards ..............................31 Late-Breaker Abstracts..........................34 Targeted Events for Students and Trainees ..........35 About the American Society of Tropical Poster Sessions ...............................37 Sunday Medicine and Hygiene November 5 Social Media ..................................39 The American Society of Tropical Medicine and Hygiene, Webcast Library of Sessions .....................39 founded in 1903, is the largest international scientific Registration ..................................40 organization of experts dedicated to reducing the worldwide Hotel........................................40 burden of tropical infectious diseases and improving global Press Room ..................................41 health. We accomplish this through generating and sharing Monday Exhibits......................................41 scientific evidence, informing health policies and practices, November 6 fostering career development, recognizing excellence, and Career Development ...........................41 advocating for investment in tropical medicine/global health Continuing Education Credit......................41 research. Speaker Ready Room...........................42 ASTMH Program Areas .........................43 Tuesday Session Topic Guide ............................44 November 7 ASTMH Council, Committee and Subgroup Meetings..52 Meeting App & Related Organization Meeting Schedule ............54 FREE Wi-Fi Exhibit Hall Floor Plan...........................59 at the Exhibitor, Sponsor and Supporter Directory ..........60 Convention Center Wednesday Detailed Program ..............................73 November 8 Poster Session A Directory.......................108 Poster Session B Directory.......................190 Poster Session C Directory.......................270 Presenter Index I ..............................348 Thursday Presenter Index II (Abstract Authors) ...............350 November 9 Baltimore Convention Center Floor Plans............385 Hilton Floor Plans ..............................388 Future Annual Meeting Dates ....................391 Presenter Index I Presenter American Society of Tropical Medicine and Hygiene One Parkview Plaza, Suite 800 Oakbrook Terrace, IL 60181 USA +1-847-686-2238 Fax +1-847-686-2253 Abstract Authors Abstract [email protected] Index II/Presenter astmh.org 7 Floor Plans ASTMH Membership Be a Member — Join ASTMH Professional Development Opportunities We invite you to join ASTMH and benefit from membership • Funding, fellowship and sponsorship opportunities tailored in the premier international organization for professionals to members’ specific research and clinical needs involved in tropical medicine and global health. ASTMH • Innovative Annual Meeting provides a forum for sharing scientific advances, exchanging • Access to the leading minds working and studying in ideas, fostering new research and providing professional tropical medicine today education. Join online at astmh.org or visit the TropMed Hub • Annual awards and scholarships for excellence across in booth 411 in the Exhibit Hall for more information. disciplines • Access to a professional network Advantages of ASTMH Membership • Members recognized as leaders in the tropical medicine • Active specialty subgroups in the areas of clinical tropical and hygiene field medicine, medical entomology, virology, global health and • Opportunities for leadership and skills-building through molecular, cellular and immunoparasitology Council, subgroup and committee participation • The Clinical Consultants Directory — a listing of physicians who offer clinical consultative service in tropical medicine, Affiliate Members medical parasitology and travelers’ health Patron • Online access to the American Journal of Tropical Medicine and Hygiene, the foremost peer-reviewed publication for communicating new findings in tropical medicine • Reduced page charges for publishing in the American Journal of Tropical Medicine and Hygiene Thank You Peter Melby, Professor; Director, UTMB Center for Tropical Educational Opportunities Diseases, Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch • Reduced registration rates for the Annual Meeting, the premier gathering of tropical medicine professionals, Contributor featuring the latest cutting-edge research and program Thank You developments via symposia, plenary and interactive Dyan Summers sessions, contributed and invited abstracts, and impromptu Zuno Health networking opportunities • Reduced rates for the Update Course in Clinical Tropical Medicine and Travelers’ Health • Examination Leading to a CTropMed® — Certificate of Knowledge in Clinical Tropical Medicine and Travelers’ Health Thank You Wilbur Milhous, Professor; Associate Dean of Research; Director, Center for Global Health Infectious Disease Research, University of South Florida Membership Dues Welcome ASTMH Members from Low and Lower-Middle Income Countries! Student (Undergraduate, Graduate, Pre-Doctoral): $15 Reduced Regular Membership Dues for Low and Trainee (Post-Doctoral, Resident, Fellow): $25 Lower-Middle Income Countries ($25) Regular Member: $250 This is open to all citizens and legal residents of World Bank low and lower-middle income countries Regular Member: Low/Lower-Middle Income Countries: $25 and WHO/HINARI classification countries of A & B. Members must be permanent residents in their Fellow of ASTMH (FASTMH): $50 voluntary contribution country of citizenship. Visiting researchers or others on short-term assignments do not qualify. Lifetime: $4,600 8 ASTMH Members are Located in 98 Countries Across Six Continents Afghanistan El Salvador Ireland Papua New Guinea Taiwan R.O.C. Argentina Equatorial Guinea Israel Peru Tanzania Australia Eritrea Italy Philippines Thailand Austria Ethiopia Ivory Coast Poland Trinidad and Tobago Bangladesh Federated States of Japan Qatar Tunisia Belgium Micronesia
Recommended publications
  • Old Road Campus

    Old Road Campus

    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
  • Diagnostic Accuracy of Procalcitonin in Critically Ill Immunocompromised

    Diagnostic Accuracy of Procalcitonin in Critically Ill Immunocompromised

    Bele et al. BMC Infectious Diseases 2011, 11:224 http://www.biomedcentral.com/1471-2334/11/224 RESEARCHARTICLE Open Access Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients Nicolas Bele1, Michael Darmon1,2,3, Isaline Coquet1, Jean-Paul Feugeas4, Stéphane Legriel1, Nadir Adaoui4, Benoît Schlemmer1 and Élie Azoulay1* Abstract Background: Recognizing infection is crucial in immunocompromised patients with organ dysfunction. Our objective was to assess the diagnostic accuracy of procalcitonin (PCT) in critically ill immunocompromised patients. Methods: This prospective, observational study included patients with suspected sepsis. Patients were classified into one of three diagnostic groups: no infection, bacterial sepsis, and nonbacterial sepsis. Results: We included 119 patients with a median age of 54 years (interquartile range [IQR], 42-68 years). The general severity (SAPSII) and organ dysfunction (LOD) scores on day 1 were 45 (35-62.7) and 4 (2-6), respectively, and overall hospital mortality was 32.8%. Causes of immunodepression were hematological disorders (64 patients, 53.8%), HIV infection (31 patients, 26%), and solid cancers (26 patients, 21.8%). Bacterial sepsis was diagnosed in 58 patients and nonbacterial infections in nine patients (7.6%); 52 patients (43.7%) had no infection. PCT concentrations on the first ICU day were higher in the group with bacterial sepsis (4.42 [1.60-22.14] vs. 0.26 [0.09- 1.26] ng/ml in patients without bacterial infection, P < 0.0001). PCT concentrations on day 1 that were > 0.5 ng/ml had 100% sensitivity but only 63% specificity for diagnosing bacterial sepsis. The area under the receiver operating characteristic (ROC) curve was 0.851 (0.78-0.92).
  • TICKS in RELATION to HUMAN DISEASES CAUSED by &lt;I

    TICKS in RELATION to HUMAN DISEASES CAUSED by <I

    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Navy Research U.S. Department of Defense 1967 TICKS IN RELATION TO HUMAN DISEASES CAUSED BY RICKETTSIA SPECIES Harry Hoogstraal Follow this and additional works at: https://digitalcommons.unl.edu/usnavyresearch This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in U.S. Navy Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. TICKS IN RELATION TO HUMAN DISEASES CAUSED BY RICKETTSIA SPECIES1,2 By HARRY HOOGSTRAAL Department oj Medical Zoology, United States Naval Medical Research Unit Number Three, Cairo, Egypt, U.A.R. Rickettsiae (185) are obligate intracellular parasites that multiply by binary fission in the cells of both vertebrate and invertebrate hosts. They are pleomorphic coccobacillary bodies with complex cell walls containing muramic acid, and internal structures composed of ribonucleic and deoxyri­ bonucleic acids. Rickettsiae show independent metabolic activity with amino acids and intermediate carbohydrates as substrates, and are very susceptible to tetracyclines as well as to other antibiotics. They may be considered as fastidious bacteria whose major unique character is their obligate intracellu­ lar life, although there is at least one exception to this. In appearance, they range from coccoid forms 0.3 J.I. in diameter to long chains of bacillary forms. They are thus intermediate in size between most bacteria and filterable viruses, and form the family Rickettsiaceae Pinkerton. They stain poorly by Gram's method but well by the procedures of Macchiavello, Gimenez, and Giemsa.
  • Coronavirus: Covid-19 Has Killed More People Than SARS and MERS Combined, Despite Lower Case Fatality Rate

    Coronavirus: Covid-19 Has Killed More People Than SARS and MERS Combined, Despite Lower Case Fatality Rate

    BMJ 2020;368:m641 doi: 10.1136/bmj.m641 (Published 18 February 2020) Page 1 of 1 News BMJ: first published as 10.1136/bmj.m641 on 18 February 2020. Downloaded from NEWS Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate Elisabeth Mahase The BMJ The novel coronavirus that has so far spread from China to 26 This comment came after the first case of covid-19 was countries around the world does not seem to be as “deadly as confirmed in Africa (in Egypt). Commenting on this milestone other coronaviruses including SARS and MERS,” the World in the outbreak, Trudie Lang, director of the Global Health Health Organization has said. Network at the University of Oxford, said it was “important but At a briefing on 17 February WHO’s director general, Tedros not unexpected.” She highlighted the fact that WHO had Adhanom Ghebreyesus, said that more than 80% of patients declared the outbreak a “public health emergency” to “support with covid-19 have a “mild disease and will recover” and that less well resourced nations in responding and preparing for it is fatal in 2% of reported cases. In comparison, the 2003 cases.” outbreak of severe acute respiratory syndrome (SARS) had a Lang praised the response of the Africa Centres for Disease case fatality rate of around 10% (8098 cases and 774 deaths), Control and Prevention, which is based in Ethiopia and supports http://www.bmj.com/ while Middle East respiratory syndrome (MERS) killed 34% countries with surveillance, emergency responses, and of people with the illness between 2012 and 2019 (2494 cases prevention of infectious disease.
  • Polymicrobial Septic Shock with Multiorgan Dysfunction in An

    Polymicrobial Septic Shock with Multiorgan Dysfunction in An

    JOMA Polymicrobial Septic Shock10.5005/jp-journals-100 with Multiorgan Dysfunction70-0012 CASE REPORT Polymicrobial Septic Shock with Multiorgan Dysfunction in an Otherwise Healthy Immunocompetent Patient 1Anuradha Makkar, 2Inam D Khan, 3KS Rajmohan, 4Syed A Hashmi, 5Lakshmi Nair, 6Alpana Gupta, 7Harleen Chopra, 8Priyanka Banerjee, 9Pragyan S Panda, 10Rajiv M Gupta ABSTRACT Source of support: Nil Background: Sepsis is a significant cause of morbidity and Conflict of interest: None mortality worldwide despite advanced critical life-support. Septic shock and multiorgan dysfunction is the terminal stage INTRODUCTION in critically ill patients leading to perfusion abnormalities, lactic acidosis, oliguria and altered mental status creating a rapid Sepsis is a major cause of morbidity and mortality world- downhill course and mortality. Sepsis ensues through stages wide despite advanced critical life-support. It is the 11th - of exaggerated immune response including systemic inflamma leading cause of death overall with attributable mortality tory response syndrome, in the backdrop of infectious stimuli. to sepsis and severe sepsis being 30 to 50% and 50 to 60%. Case report: Polymicrobial septic shock with multiorgan Following a non-infectious or infectious insult, there is dysfunction leads to demise in an otherwise healthy immuno- competent patient. Microbiological profile revealedEscherichia a preliminary systemic response which becomes over- coli urinary tract infection (UTI), Staphylococcus sciuri bactere- whelming leading to systemic inflammatory response mia, Acinetobacter baumanii ventilator-associated pneumonia, syndrome. When the compensatory anti-inflammatory and central line catheter tip Pseudomonas aeruginosa, thereby reaction fails, it leads to immunomodulatory failure, pointing towards polymicrobial sepsis. Neutropenia of 290/ dL along with serum procalcitonin 5 ng/mL was detected.
  • Anchoring the African Internet Ecosystem

    Anchoring the African Internet Ecosystem

    Anchoring the African Internet Ecosystem Anchoring the African Internet Ecosystem: Lessons from Kenya and Nigeria’s Internet Exchange Point Growth By Michael Kende June 2020 CC BY-NC-SA 4.0 internetsociety.org 1 Anchoring the African Internet Ecosystem Table of contents 3 Executive summary 6 Background: A vision for Africa 8 Introduction: How to get there from here 13 Success stories: Kenya and Nigeria today 18 Results that stand the test of time 20 Change factors: Replicable steps toward measurable outcomes 27 Market gaps 29 Recommendations 33 Conclusions 34 Annex A: Kenya Internet Exchange Point 35 Annex B: Internet Exchange Point of Nigeria 36 Annex C: Acknowledgments 37 Annex D: Glossary of terms 38 Annex E: List of figures and tables CC BY-NC-SA 4.0 internetsociety.org 2 Anchoring the African Internet Ecosystem Executive summary In 2010, the Internet Society’s team in Africa set an The rapid pace of Internet ecosystem ambitious goal that 80% of African Internet traffic development in both Kenya and Nigeria since would be locally accessible by 2020. 2012 underscores the critical role that IXPs Internet Exchange Points (IXPs) are key to realizing and the accompanying infrastructure play in this goal in that they enable local traffic exchange and the establishment of strong and sustainable access to content. To document this role, in 2012, the Internet ecosystems. Internet Society commissioned a study to identify and quantify the significant benefits of two leading African This development produces significant day-to-day IXPs at the time: KIXP in Kenya and IXPN in Nigeria. value—the present COVID-19 crisis magnifies one such The Internet Society is pleased to publish this update benefit in the smooth accommodation of sudden of the original study.
  • CTRI Trial Data

    CTRI Trial Data

    PDF of Trial CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Tue, 28 Sep 2021 15:39:14 GMT) CTRI Number CTRI/2009/091/001080 [Registered on: 28/06/2010] - Last Modified On Post Graduate Thesis Type of Trial Type of Study Study Design Randomized, Parallel Group, Placebo Controlled Trial Public Title of Study A clinical Trial to study the safety, immunogenicity and tolerability of a tetravalent rotavirus vaccine in Indian infants. Scientific Title of Phase I/II, randomized, double-blind, placebo-controlled, dosage selection (10e5.5 or 10e6.25 FFU Study of each constituent serotype per 0.5 mL) study to evaluate the safety, tolerability, and immunogenicity of a 3-dose series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] administered to healthy Indian infants. Secondary IDs if Any Secondary ID Identifier NCT01061658 ClinicalTrials.gov SBL/BRV-TV/Form1/PhI/2009/0100 Protocol Number SBL/BRV-TV/Form1/PhI/2009/0100 Protocol Number Details of Principal Details of Principal Investigator Investigator or overall Name Dr. Gagandeep Kang Trial Coordinator (multi-center study) Designation Affiliation Address Department of Gastrointestinal Sciences, Christian Medical College Vellore TAMIL NADU 632004 India Phone 0416-2282052 Fax 0416-2282486 Email [email protected] Details Contact Details Contact Person (Scientific Query) Person (Scientific Name Dr. Raman Rao Query) Designation Affiliation Shantha Biotechnics Limited Address VP, R&D, 4th Floor, Vasantha Chambers, Fateh Maidan Road, Basheer Bagh Hyderabad ANDHRA PRADESH 500004 India Phone 040-66301800 Fax 040-23234133 Email [email protected] Details Contact Details Contact Person (Public Query) Person (Public Query) Name Dr.

  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K

    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
  • “Women Rarely Put Themselves Forward Despite Being Very Capable.”

    “Women Rarely Put Themselves Forward Despite Being Very Capable.”

    IN CONVERSATION “Women rarely put themselves forward despite being very capable.” Professor Gagandeep Kang is currently the Executive Director of Translational Health Science and Technology Institute (THSTI), Faridabad. She is the first Indian woman scientist to be elected as Fellow of Royal Society (FRS) by the Royal Society in the UK. She is a leading scientist with over 300 scientific research papers published on diarrhoeal infections in children, mainly from work done at the Christian Medical College (CMC) in Vellore. Amongst several awards, she is the recipient of the Infosys Life Sciences Award in 2016. She is a member of many review and advisory committees for national and international funding agencies related to public health. Dr. Kang has chaired the WHO SEAR’s Regional Immunization Technical Advisory Group since 2015. In an interview given to PARUL R. SHETH for Science Reporter, Dr Gagandeep Kang talks about her work on rotaviruses, safety of Indian vaccines, the advantages and disadvantages of being a woman in science, and her experiences with community health programmes. 20 | Science Reporter | June 2019 GAGANDEEP KANG: My colleague, Ira and I published a PARUL R. SHETH: Congratulations to you for being the paper a couple of years ago, comparing children of doctors and first woman scientist to be elected as FRS in 360 years! This children who lived in urban slum areas, showing that middle indeed is a great honour and we are all proud of you. Your class Indian children carry in their guts one-fourth the number work has been recognised for its quality and impact.
  • Maternal Mortality and HIV: an Overview

    Maternal Mortality and HIV: an Overview

    Maternal Mortality and HIV: An Overview Contextual factors such as local policies and cultural norms, as well as socioeconomic factors, play a role in women’s ability to access care and receive appropriate treatment during pregnancy, childbirth, and postpartum.1 This is true for all women, and particularly so for the 17 million women living with HIV globally, the vast majority of whom live in sub-Saharan Africa (SSA) and are of reproductive age.2 In 2013, HIV was responsible for 1.5% of all maternal Adult HIV prevalence rates, 2012 data from Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. deaths in SSA and 0.4% worldwide.3 Pregnant women living with HIV have between a two to 10 times increased risk of death than uninfected pregnant women.4,5,6,7,8 While maternal deaths have decreased overall in the past decade, countries with high HIV burdens have had slower declines compared to countries less affected by the HIV pandemic. For example, South Africa—an upper middle-income country with an HIV infection rate among pregnant women aged 15-49 years of 29.5%9—experienced a decrease of only 0.4% in its maternal mortality ratio (MMR) between 1990 and Data on maternal mortality ratio (per 100,000 live births) from World 2013, despite a global MMR decrease of 45% in the Health Organization 2012. same timeframe10. CAUSES OF MATERNAL MORBIDITY AND MORTALITY AMONG WOMEN LIVING WITH HIV The World Health Organization (WHO) defines maternal death as “the death of a woman during pregnancy or within 42 days of termination of pregnancy irrespective
  • Introduction to the Maternal and Newborn Quality of Care Surveys

    Introduction to the Maternal and Newborn Quality of Care Surveys

    INTRODUCTION TO THE MATERNAL AND NEWBORN QUALITY OF CARE SURVEYS Introduction To The Quality of Care Surveys i The Maternal and Child Health Integrated Program (MCHIP) is the United States Agency for International Development’s Bureau for Global Health flagship maternal, neonatal and child health program. MCHIP supports programming in maternal, newborn and child health, immunization, family planning, malaria and HIV/AIDS, and strongly encourages opportunities for integration. Cross-cutting technical areas include water, sanitation, hygiene, urban health and health systems strengthening. This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Leader with Associates Cooperative Agreement GHS-A-00-08-00002-00. The contents are the responsibility of the Maternal and Child Health Integrated Program (MCHIP) and do not necessarily reflect the views of USAID or the United States Government. Published by: Jhpiego Brown’s Wharf 1615 Thames Street Baltimore, Maryland 21231-3492, USA January 2013 Introduction To The Quality of Care Surveys ii 1. BACKGROUND Improving the quality of obstetric care in facilities has recently been identified as a neglected and essential approach to reducing maternal deaths and enabling developing countries to achieve Millennium Development Goal (MDG) 4 and 5.1 Postpartum hemorrhage is the most frequent cause of maternal deaths globally and in developing countries, accounting for 25% of maternal deaths. Next are hypertensive disorders in pregnancy (PE/E) at 15%, sepsis (8%) and obstructed labor (7%).2 Effective interventions exist for screening, preventing and treating obstetric and newborn complications, and they can be readily provided by skilled providers in facilities.
  • Quotes on Rotavirus Vaccine News

    Quotes on Rotavirus Vaccine News

    Additional statements on ROTASIIL® Phase 3 India clinical trial results It is important to have a new approach to look at rotavirus vaccine efficacy. Rotavirus vaccination in developing countries has always struggled with interpretation of efficacy through use of markers of seroconversion or reduction of death in the community. Both are erroneous because of babies being breastfed as well as high infant mortality under five years of age in certain geographic regions of India. Better indicators have been surrogate indicators, which reflect fewer admissions of children to the hospital related to rotavirus as well as a reduced stay in the hospital due to the same. These markers have worked well in Mexico and El Salvador. Prof. N.K. Ganguly, Former Director General, Indian Council of Medical Research; Visiting Professor of Eminence, Policy Center for Biomedical Research, Translational Health Science & Technology Institute, Faridabad, India India now has another rotavirus vaccine that is manufactured indigenously. This is a win for the children of the country as it will support the Government of India’s efforts to roll out the rotavirus vaccine across the country through the Universal Immunization Programme. Dr. M.K. Bhan, Former Secretary, Department of Biotechnology, Government of lndia I am delighted that India has another rotavirus vaccine. Scientific studies have shown that rotavirus vaccines are making a major public health impact. Swift and significant declines in hospitalizations and deaths due to rotavirus and all‐cause diarrhea have been observed in many of the countries that have introduced rotavirus vaccines into their national immunization programs. Dr. Gagandeep Kang, Executive Director of Translational Health Science & Technology Institute, Faridabad, India, and member of the ROTA Council Rotavirus is the most common cause of diarrhea and one of the leading cause of under‐five child mortality.